文献速递系统性红斑狼疮

系统性红斑狼疮临床试验的困境:为何III期试验未能证实II期试验的乐观结果

Clinical trials in systemic lupus erythematosus: the dilemma-Why have phase III trials failed to confirm the promising results of phase II trials?
PubMed 文献 · Ann Rheum Dis · 2022-10-06

该综述聚焦系统性红斑狼疮(SLE)II期与III期试验结果不一致的困境,重点分析依帕珠单抗(抗CD22)、巴瑞替尼(Janus激酶抑制剂)、利格里莫德(P140肽)和乌司奴单抗(IL-12和IL-23抑制剂)的II期与III期试验,并探讨II期试验获得良好结果而III期试验最终失败的可能原因。

要点

  • SLE患者病情反复复发缓解,即使接受看似充分的治疗仍可复发,提示需要更有效的疗法。
  • 多种针对不同靶点(如CD22、IL-12和IL-23、酪氨酸激酶)的药物已开展试验。
  • 部分生物制剂在II期试验成功后,III期试验未能证实其疗效,构成临床研发困境。

核心结论

  • 部分生物制剂在SLE的II期试验中报告成功,但随后的III期试验失败,该综述重点分析依帕珠单抗、巴瑞替尼、利格里莫德和乌司奴单抗的II期与III期试验并探讨其最终未能达标的原因。

研究设计与样本

  • 综述,聚焦依帕珠单抗(抗CD22)、巴瑞替尼(Janus激酶抑制剂)、利格里莫德(P140肽)和乌司奴单抗(IL-12和IL-23抑制剂)的II期与III期试验。

主要发现

  • SLE患者即使接受看似充分的治疗仍可出现复发,提示需要更有效的疗法。
  • 针对CD22、IL-12和IL-23或酪氨酸激酶等多种不同靶点的药物试验已在近年开展。
  • 部分用于SLE的生物制剂在II期试验报告成功后,III期试验未能证实其疗效。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease of unknown aetiology, characterised by the production of auto-antibodies and formation of immune complexes against self-antigens and complement activation. This inflammatory response can lead to tissue infiltration and eventually, to organ damage.Patients with SLE invariably have periods of relapse and remission. Flares can occur even when the patient is on seemingly adequate treatment, which suggests that more effective therapies are necessary for the management of SLE. Thus, trials with many drugs against different targets, such as CD22, IL-12 and IL-23 or tyrosine kinases, have been carried out in recent years.A frustrating feature of some of the biologic drugs used to treat SLE has been the reporting of successful phase II trials followed by failures of the phase III trials.In this review, we will focus on phase II and III trials carried out with epratuzumab (anti CD22), baricitinib (Janus kinases inhibitor), rigerimod (P140 peptide) and ustekinumab (IL-12 and IL-23 inhibitor) and consider the reasons for their ultimate failure to 'make the grade'. Likewise, we will try to explain the possible reasons that can influence why good results may be obtained in phase II trials and lead to undue optimism.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Lorenzo-Vizcaya A, Isenberg DA. Clinical trials in systemic lupus erythematosus: the dilemma-Why have phase III trials failed to confirm the promising results of phase II trials? Ann Rheum Dis. 2022. PMID: 36202589. doi:10.1136/ard-2022-222839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。